Literature DB >> 7658340

Influence of pH, temperature, and buffers on the kinetics of ceftazidime degradation in aqueous solutions.

M Zhou1, R E Notari.   

Abstract

First-order rate constants (k) were determined for the hydrolysis of ceftazidime in the pH range of 0.5 to 8.5 at 45, 55, and 65 degrees C by a stability-indicating HPLC assay. In the absence of buffer effects, the pH-rate expression was k = kH1f1(aH+) + kH2f2(aH+) + kH3f3(aH+) + kSf3 + kOHf3(aOH-), where KH and KOH are the catalytic rate constants for the activity of hydrogen (aH+) and hydroxyl (aOH-) ions, respectively, and kS is the rate constant for spontaneous hydrolysis. The fractions of ceftazidime in various stages of dissociation (f1, f2, and f3) were calculated from kinetically determined apparent Ka values of 2.03 x 10(-2) and 4.85 x 10(-5). Catalytic constants (kcat) were calculated for formate, acetate, phosphate, and borate buffers, which accelerated hydrolysis. Each of the rate constants (kH1, kH2, kH3, kS, kOH, and kcat) were described as a function of temperature with calculated A and E values in the Arrhenius equation, kT = Ae-E/RT. Ceftazidime hydrolysis rate constants (k) were calculated as a function of pH, temperature, and buffer by combining the pH-rate expression with the buffer contributions calculated from kcat values and the temperature dependencies. These equations and their parameter values successfully calculated 95 of 104 experimentally determined rate constants with errors of < 10%. Maximum stability was observed in the relatively pH-independent region from 4.5 to 6.5. Hydrolysis rate constants at 30 degrees C were predicted and experimentally verified for four ceftazidime solutions, three of which (pH 4.4 acetate buffer and pH 5.5 and 6.5 phosphate buffers) maintained 90% of their initial concentration for approximately 1.5 days.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7658340     DOI: 10.1002/jps.2600840504

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  5 in total

1.  How to minimize toxic exposure to pyridine during continuous infusion of ceftazidime in patients with cystic fibrosis?

Authors:  P Bourget; A Amin; C Dupont; M Abely; N Desmazes-Dufeu; J C Dubus; B-L Jouani; C Merlette; R Nové-Josserand; J Pages; R Panzo; F Vidal; F Voge; D Hubert
Journal:  Antimicrob Agents Chemother       Date:  2014-03-10       Impact factor: 5.191

2.  Stability and compatibility of ceftazidime administered by continuous infusion to intensive care patients.

Authors:  H Servais; P M Tulkens
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

3.  Comparative stability studies of antipseudomonal beta-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units).

Authors:  Eric Viaene; Hugues Chanteux; Hélène Servais; Marie-Paule Mingeot-Leclercq; Paul M Tulkens
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

4.  Crystal structures of penicillin-binding protein 3 from Pseudomonas aeruginosa: comparison of native and antibiotic-bound forms.

Authors:  Sarah Sainsbury; Louise Bird; Vincenzo Rao; Sharon M Shepherd; David I Stuart; William N Hunter; Raymond J Owens; Jingshan Ren
Journal:  J Mol Biol       Date:  2010-10-23       Impact factor: 5.469

5.  Optimization of liposomal encapsulation for ceftazidime for developing a potential eye drop formulation.

Authors:  Chamari Wijesooriya; Marianna Budai; Lívia Budai; Magdolna E Szilasi; Ilona Petrikovics
Journal:  J Basic Clin Pharm       Date:  2013-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.